Switzerland · Delayed Price · Currency is CHF Basilea Pharmaceutica AG Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 14% year-on-year to CHF 119 million, with operating profit up 32% and net profit at CHF 27.9 million. Strong Cresemba sales and Zevtera's U.S. launch drove growth, while guidance for 2026 was raised, reflecting higher expected revenue and profitability.
Fiscal Year 2025
-
2025 saw robust revenue and profit growth, driven by Cresemba's global momentum and Zevtera's U.S. launch. The pipeline expanded with new phase 3 assets, and significant non-dilutive funding was secured, positioning for sustained growth despite upcoming generic competition for Cresemba.
-
Strong H1 2025 results driven by Cresemba's robust sales and Zevtera's U.S. launch, with total revenue up 36% year-on-year. Pipeline expanded with a new oral antibiotic, and 2025 guidance raised for revenue and operating profit, despite expected product revenue decline from Pfizer supply.
Fiscal Year 2024
-
Strong 2024 results featured a tripling of operating profit and robust revenue growth, driven by Cresemba and Zevtera. The pipeline expanded with new antifungal and antibiotic assets, and significant non-dilutive funding was secured. 2025 guidance anticipates continued revenue and profit growth.
-
Strong H1 2024 results driven by Cresemba growth and Zevtera U.S. approval led to raised full-year guidance. Pipeline expanded with four new anti-infective programs, and significant milestone payments are expected in H2. Debt reduction and stable expenses support a positive outlook.